Business Wire

Paul Fry appointed as Argenta’s new Chief Financial Officer

Share

Argenta today announced that Paul Fry will join the company as its new Chief Financial Officer, starting immediately. To ensure a smooth transition, Paul will work closely with former CFO Chris O’Donnell until late August.

The CFO role is being relocated from New Zealand to London to enable the CEO and CFO to work closely together in the same time zone, and to be closer to customers and new commercial opportunities.

Chris O’Donnell, who has served as Argenta’s CFO since 2018, is supportive of the decision and has decided to stay in New Zealand. He stepped down from his role on June 24 and will stay on until August 26 to support with the transition. Chris has played a leading role in the success and growth of Argenta, providing skilful oversight to key projects including the transition of ownership to KKR and the acquisition of Klifovet.

Paul Fry has extensive financial experience across several industries including biotech, pharmaceuticals, and telecommunications. Prior to joining Argenta, he was Chief Financial Officer of Vectura Group plc, an industry-leading inhaled drug delivery specialist which was listed on the main market of the London Stock Exchange until 2021. In his time with the company, he played an instrumental role in almost doubling its market valuation.

Before Vectura, Paul was Chief Financial Officer of Immunocore Limited, a leading biotech company focused on the development of a new class of immunotherapeutic drugs based on proprietary T-cell receptor (TCR) technology. He also served as Director of Global Finance Operations at Vodafone plc and spent more than 25 years at GSK, where he held several senior leadership roles.

Will Downie, CEO of Argenta, said: “I am delighted to welcome Paul to Argenta. His proven track record and extensive experience, combined with his strategic financial expertise and outstanding leadership qualities, will have a significant impact on the company. I am excited to partner with Paul to help drive long-term growth and scale for the organization.

“I would also like to take this opportunity to express my gratitude to Chris O’Donnell for his commitment, partnership, and financial stewardship in the time we have worked together. Chris has helped to lay the solid foundation that supports the company's ambitious strategy.”

Paul Fry said: “It is an exciting time to enter the animal health industry and I am delighted to be joining Argenta. The company has a unique offering, strong track record and the potential for significant growth for many years to come. I feel privileged to be able to contribute to this and to have the opportunity to serve Argenta’s customers, team members and shareholders.”

Paul holds a degree from Oxford University and is a member of the Chartered Institute of Management Accounts. He is also a Non-executive Director and Chair of the Audit Committee at Avacta plc, an AIM-listed biotech company developing diagnostics and new oncology therapies.

About Argenta

Argenta is the only combined global Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) dedicated to animal health. Founded in 2006 in New Zealand, Argenta’s talented, diverse, and committed employees are driven to deliver excellence in animal health to customers around the world. With research and GMP manufacturing operations in New Zealand, the United States, the United Kingdom, and Germany, Argenta operates from ‘Molecule to Market’ in partnership with its customers to support their R&D, regulatory, clinical research, and manufacturing needs along the veterinary product development journey. For more information about Argenta, please visit www.argentaglobal.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press
Annemieke de Keijzer
+1 732-439-3446
globalcommunications@argentaglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Feeling ’22: Mary Kay Inc. Announces Awards, Milestones, and Accomplishments From First Half of the Year28.7.2022 20:02:00 EEST | Press release

Mary Kay Inc. is feeling ’22. Throughout the first half of the year, the iconic global entrepreneurship company has furthered its innovations in skin science, continued its social impact efforts, and garnered several prestigious awards for its business and leadership. It’s a thing of beauty—and the nearly 60-year-old brand is just getting started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220728005228/en/ Mary Kay logo (Graphic: Mary Kay Inc.) 2022 AWARDS & HIGHLIGHTS 30 total awards for business excellence, social impact and sustainability 10 employer awards recognizing Mary Kay as a great place to work and for operational excellence 7 awards for Mary Kay’s c-suite and senior leadership 17 self-released reports reinforcing Mary Kay’s operational and philanthropic efforts supporting its sustainability commitments for its Enriching Lives Today for a Sustainable Tomorrow strategy 3 mentions in annual reports from social i

Asaf Ashkenazi Named CEO of Verimatrix28.7.2022 19:00:00 EEST | Press release

Regulatory News: Verimatrix (Euronext Paris: VMX) (Paris:VMX), today announced the appointment of Asaf Ashkenazi as Chief Executive Officer effective Monday, August 1st, 2022. Amedeo D’Angelo, Chairman and Chief Executive Officer since 2015, remains Executive Chairman of Verimatrix effective the same day. Asaf Ashkenazi joined Verimatrix in 2018 and currently serves as Chief Operating Officer. He will lead the company’s ongoing business model transformation announced last year that focuses on recurring subscription-based revenue sources and new products. “This evolution and reinforcement of the Verimatrix governance structure aligns well with the company’s needs as we further the progression of our business model,” Amedeo D’Angelo said. “I look forward to working closely with Asaf in his newly expanded role as CEO during this strategic development of Verimatrix.” Previously leading the company’s R&D, product, sales and marketing operations, Asaf Ashkenazi will continue to harness his d

GUESS Heads to Granada for the 2022 Fall/Winter Advertising Campaign28.7.2022 18:00:00 EEST | Press release

The new GUESS Fall-Winter 2022 advertising campaign sees the brand off to explore the history-steeped streets of Granada, Spain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220728005098/en/ GUESS Heads to Granada for the 2022 Fall/Winter Advertising Campaign (Photo: Business Wire) The FW22 campaign is immortalized through the lens of fashion photographer Tatiana Gerusova, under the guidance of GUESS?, Inc.’s Chief Creative Officer, Paul Marciano. The new campaign features a sizzling lineup: German-born, Polish fashion model Kim Dammer, Serbian model Nina Kostić, Spanish model Lidia Santos, Italian model Mario Ermito, and French model Xavier Grey. GUESS Women The campaign showcases an enticing array of GUESS pieces, highlighting must-have accessories and elevated animal and botanical prints. The collection brings a fresh and youthful breeze of contemporary color and style to grey winter days. Against the alluring continent

Innovaderm Bolsters European Presence With Two Newly-Established Operations Hubs (Spain & Poland)28.7.2022 17:00:00 EEST | Press release

Innovaderm announced today that its strategic European expansion initiative has reached a major milestone with the launch of two key centres of operations in Poland and Spain. Biotechnology and pharmaceutical companies can officially partner with the CRO’s team of experts in Europe to manage clinical trials in psoriasis, acne, atopic dermatitis and other dermatology indications. This includes adherence to stringent regulatory requirements, patient recruitment, site selection, clinical monitoring and protocol writing. “To date, we have successfully completed more than 500 clinical trials at 2,900 sites,” says Dave Selkirk, Innovaderm’s Chief Operating Officer. “The presence of two operations hubs in Europe will allow us to go one step further and accelerate the development of promising therapies that have the potential to transform lives. As we look to the future, our goal is to continue supporting innovation in research and the increasing number of patients with skin conditions worldwi

Echosens Partners with World Hepatitis Alliance on World Hepatitis Day, July 28, Urges Importance of Testing and Treatment28.7.2022 16:07:00 EEST | Press release

Echosens, a high-technology company offering liver diagnostic solutions, establishes its support of World Hepatitis Day (WHD), July 28 by partnering with the World Hepatitis Alliance as a bronze sponsor. The commemoration calls for greater awareness of the 357 million people who live with viral hepatitis but are unaware of it. The campaign’s theme “I can’t wait” highlights the need to accelerate the fight against viral hepatitis and the importance of testing and treatment for the real people who need it. “Echosens recognizes that every 30 seconds, someone in the world dies from a hepatitis-related illness, and we join hands with organizations throughout the world to advance increased vigilance around liver health,” says Dominque Legros, Echosens Group CEO. “It is gratifying to see that this year's theme for World Hepatitis Day aligns with our mission for early detection that can result in more effective intervention, treatment and better outcomes.” Viral hepatitis is an inflammation of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom